Compelling drug indications in diabetic and nondiabetic nephropathy

Current Hypertension Reports

Volumn 6, Issue 4, 2004, Pages 293-299

  Ritz, Eberhard ^a   Dikow, Ralf ^a   Zeier, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; NISOLDIPINE; PLACEBO; RAMIPRIL; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG CHOICE; DRUG INDICATION; DRUG PENETRATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE;

EID: 4344715761     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0024-6     Document Type: Review

References (87)

1. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982, 307:652-659.
2. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
3. Adamczak M, Gross ML, Krtil J, et al.: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14:2833-2842.
4. Fogo AB: Regression lines in chronic kidney disease. J Am Soc Nephrol 2003, 14:2990-2991.
5. Adamczak M, Zeier M, Dikow R, Ritz E: Kidney and hypertension. Kidney Int Suppl 2002, 80:62-67.
6. Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003, 42:1050-1065.
7. Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
8. Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
9. Gaede PH, Jepsen PV, Larsen JN, et al.: [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskr Laeger 2003, 165:2658-2661.
10. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
11. Adler AI, Stevens RJ, Manley SE, et al.: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
12. Coresh J, Astor BC, Greene T, et al.: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
13. Levey AS, Coresh J, Balk E, et al.: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
14. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217-222.
15. Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555-1565.
16. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
17. Ruggenenti P, Perna A, Gherardi G, et al.: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998, 352:1252-1256.
18. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
19. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
20. Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
21. Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
22. Campbell RC, Ruggenenti P, Remuzzi G: Proteinuria in diabetic nephropathy: treatment and evolution. Curr Diab Rep 2003, 3:497-504.
23. Eknoyan G, Hostetter T, Bakris GL, et al.: Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003, 42:617-622.
24. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990, 38:384-394.
25. Gross ML, Hanke W, Koch A, et al.: Intraperitoneal protein injection in the axolotl: the amphibian kidney as a novel model to study tubulointerstitial activation. Kidney Int 2002, 62:51-59.
26. Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003, 63:2254-2261.
27. Wilmer WA, Rovin BH, Hebert CJ, et al.: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003, 14:3217-3232.
28. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877-884.
29. Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754-762.
30. Ritz E, Koomans HA: New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant 1996, 11(Suppl2):52-59.
31. Mogensen CE, Viberti G, Halimi S, et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in Albuminuria Regression: PREMIER. Hypertension 2003, 41:1063-1071.
32. Wilcox CS: New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:798-805.
33. Fliser D, Zurbruggen I, Mutschler E, et al.: Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999, 55:629-634.
34. Stefanski A, Schmidt KG, Waldherr R, Ritz E: Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996, 50:1321-1326.
35. Ritz E, Schwenger V, Zeier M, Rychlik I: Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 2001, 16:1550-1554.
36. Tozawa M, Iseki K, Yoshi S, Fukiyama K: Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999, 14:1976-1981.
37. Nakano S, Ogihara M, Tamura C, et al.: Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. J Diabetes Complications 1999, 13:224-231.
38. Reubi FC, Weidmann P, Gluck Z: Interrelationships between sodium clearance, plasma aldosterone, plasma renin activity, renal hemodynamics and blood pressure in renal disease. Klin Wochenschr 1979, 57:1273-1285.
39. Kuczera M, Hilgers KF, Lisson C, et al.: Local angiotensin formation in hindlimbs of uremic hypertensive and renovascular hypertensive rats. J Hypertens 1991, 9:41-48.
40. Thompson MM, Oyama TT, Kelly FJ, et al.: Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1787-1794.
41. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382-2391.
42. Epstein M: Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003, 18:1984-1992.
43. Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003, 14:2395-2401.
44. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
45. Converse RL Jr, Jacobsen TN, Toto RD, et al.: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
46. Klein IH, Ligtenberg G, Oey PL, et al.: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001, 12:2427-2433.
47. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004, 15:524-537.
48. Fliser D, Pacini G, Engelleiter R, et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998, 53:1343-1347.
49. Chen J, Muntner F, Hamm LL, et al.: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003, 14:469-477.
50. Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998, 13:3091-3095.
51. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
52. American Diabetes Association and the National Kidney Foundation: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357-1361.
53. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461-1464.
54. Lurbe E, Redon J, Kesani A, et al.: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
55. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
56. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
57. Marre M, Lievre M, Chatellier G, et al.: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004, 328:495.
58. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994, 271:275-279.
59. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
60. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
61. Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003, 26:3296-3302.
62. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.
63. Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
64. Laverman GD, de Zeeuw D, Navis G: Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 2002, 3:205-213.
65. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
66. Schwartz MM, Lewis EJ, Leonard-Martin T, et al.: Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998, 13:2547-2552.
67. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001, 345:910-912.
68. Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002, 20:125-130.
69. Segura J, Christiansen H, Campo C, Ruilope LM: How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep 2003, 5:426-429.
70. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
71. Andersen NH, Knudsen ST, Poulsen PL, et al.: Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. J Renin Angiotensin Aldosterone Syst 2003, 4:96-99.
72. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268-2274.
73. Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159-164.
74. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
75. Peters H, Border WA, Noble NA: Targeting TGF-beta over-expression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54:1570-1580.
76. Ots M, Mackenzie HS, Troy JL, et al.: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998, 9:224-230.
77. Palla R, Panichi V, Finato V, et al.: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994, 14:35-43.
78. Andrade AQ, Casarini DE, Schor N, Boim MA: Characterization of renin mRNA expression and enzyme activity in rat and mouse mesangial cells. Braz J Med Biol Res 2002, 35:17-24.
79. Durvasula RV, Petermann AT, Hiromura K, et al.: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30-39.
80. Seikaly MG, Arant BS Jr, Seney FD Jr: Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990, 86:1352-1357.
81. Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int Suppl 1993, 39:S100-107.
82. Hsieh TJ, Fustier P, Zhang SL, et al.: High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003, 144:4338-4349.
83. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002, 39:129-134.
84. Fioretto P, Steffes MW, Sutherland DE, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
85. Remuzzi A, Gagliardini E, Donadoni C, et al.: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002, 62:885-894.
86. Zoja C, Corna D, Camozzi D, et al.: How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002, 13:2898-2908.
87. Hostetter TH: The next treatments of chronic kidney disease: if we find them, can we test them? J Am Soc Nephrol 2002, 13:3024-3026.